image credit: Unsplash

Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

August 12, 2020

Via: BioSpace

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended June 30, 2020 and provided a business update.

Read More on BioSpace